Burzynski Research Institute Inc (BZYR) — SEC Filings
Burzynski Research Institute Inc (BZYR) — 10 SEC filings. Latest: 10-Q (Oct 14, 2025). Includes 6 10-Q, 2 10-K, 1 8-K/A.
View Burzynski Research Institute Inc on SEC EDGAR
Overview
Burzynski Research Institute Inc (BZYR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Oct 14, 2025: Burzynski Research Institute, Inc. (BZYR) reported a net loss of $333,867 for the three months ended August 31, 2025, a 9.7% improvement from the $369,838 net loss in the same period of 2024. For the six months ended August 31, 2025, the net loss was $665,318, an 11.4% improvement from the $741,170
Sentiment Summary
Across 10 filings, the sentiment breakdown is: 2 bearish, 8 neutral. The dominant filing sentiment for Burzynski Research Institute Inc is neutral.
Filing Type Overview
Burzynski Research Institute Inc (BZYR) has filed 6 10-Q, 1 8-K/A, 1 8-K, 2 10-K with the SEC between Jan 2024 to Oct 2025.
Filings by Year
Recent SEC Filings (10)
| Date | Form | Description | Risk |
|---|---|---|---|
| Oct 14, 2025 | 10-Q | Burzynski Research Institute Narrows Loss Amid FDA Hold, Funding Reliance | high |
| Sep 11, 2025 | 8-K/A | Burzynski Research Institute Files Amendment on Accountant Change | low |
| Jul 24, 2025 | 8-K | Burzynski Research Institute Changes Certifying Accountant | medium |
| Jul 15, 2025 | 10-Q | Burzynski Research Institute Q1 Equity Shifts Noted | high |
| May 20, 2025 | 10-K | Burzynski Research Institute Files 2025 10-K | low |
| Jan 13, 2025 | 10-Q | Burzynski Research Institute Files Q3 2025 10-Q | low |
| Oct 10, 2024 | 10-Q | Burzynski Research Institute Inc. Files 10-Q | low |
| Jul 15, 2024 | 10-Q | Burzynski Research Institute Inc. Files 10-Q | low |
| May 29, 2024 | 10-K | Burzynski Research Institute Files 2024 10-K | low |
| Jan 16, 2024 | 10-Q | Burzynski Research Institute Inc. Files 10-Q for Period Ending November 30, 2023 | low |
Risk Profile
Risk Assessment: Of BZYR's 10 recent filings, 2 were flagged as high-risk, 1 as medium-risk, and 7 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | $ (333,867) |
| EPS | $ (0.00) |
| Debt-to-Equity | N/A |
| Cash Position | $931 |
| Operating Margin | N/A |
| Total Assets | $1,331 |
| Total Debt | $0 |
Key Executives
- S.R. Burzynski M.D., Ph.D.
Industry Context
The pharmaceutical industry, particularly in oncology, is highly competitive and capital-intensive, with long development cycles and significant regulatory hurdles. Companies like Burzynski Research Institute operate in a space where groundbreaking therapies are sought, but success is contingent on rigorous clinical trials and FDA approval. The industry trend is towards targeted therapies and personalized medicine, requiring substantial investment in research and development.
Top Tags
10-Q (5) · financials (5) · auditor-change (2) · 10-K (2) · quarterly-report (2) · diagnostics (2) · Biotechnology (1) · Clinical Trials (1) · FDA Regulation (1) · Going Concern (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Six Months) | $665,318 | Improved by 11.4% from $741,170 in prior year, but still significant. |
| Accumulated Deficit | $130,141,731 | Indicates substantial historical losses and financial instability. |
| Capital Contribution by Dr. Burzynski | $637,384 | Represents 100% of funding for the six months ended August 31, 2025, highlighting economic dependency. |
| Cash and Cash Equivalents | $931 | Extremely low cash balance as of August 31, 2025, indicating liquidity issues. |
| Common Shares Outstanding | 131,448,444 | Consistent share count, but no market value due to lack of exchange listing. |
| Revenue from External Sources | 0% | Company has no significant revenue, relying solely on related-party funding. |
| Ownership by Dr. Burzynski | 81.0% | Highlights concentrated control and related-party risk. |
| Accrued Liabilities | $46,959 | Increased from $25,467, primarily due to legal and audit fees. |
| Quarter End Date | 2025-05-31 | Period of report for the 10-Q filing |
| Employee Stock Option Grant Date | 1996-09-14 | Earliest recorded employee stock option grant date |
| Fiscal Year End | FY 2025 --02-28 | Reporting period for the 10-K |
| Retained Earnings | 2025-02-28 | As of the fiscal year end 2025 |
| Additional Paid-In Capital | 2025-02-28 | As of the fiscal year end 2025 |
| Reporting Period End Date | 2024-11-30 | Indicates the end of the financial reporting period covered by the 10-Q. |
| Filing Date | 2025-01-13 | The date the 10-Q was officially submitted to the SEC. |
Frequently Asked Questions
What are the latest SEC filings for Burzynski Research Institute Inc (BZYR)?
Burzynski Research Institute Inc has 10 recent SEC filings from Jan 2024 to Oct 2025, including 6 10-Q, 2 10-K, 1 8-K/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of BZYR filings?
Across 10 filings, the sentiment breakdown is: 2 bearish, 8 neutral. The dominant sentiment is neutral.
Where can I find Burzynski Research Institute Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Burzynski Research Institute Inc (BZYR) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Burzynski Research Institute Inc?
Key financial highlights from Burzynski Research Institute Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for BZYR?
The investment thesis for BZYR includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Burzynski Research Institute Inc?
Key executives identified across Burzynski Research Institute Inc's filings include S.R. Burzynski M.D., Ph.D..
What are the main risk factors for Burzynski Research Institute Inc stock?
Of BZYR's 10 assessed filings, 2 were flagged high-risk, 1 medium-risk, and 7 low-risk.
What are recent predictions and forward guidance from Burzynski Research Institute Inc?
Forward guidance and predictions for Burzynski Research Institute Inc are extracted from SEC filings as they are enriched.